Compare DexCom, Inc. (DXCM) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Warner Music Group Corp — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Warner Music Group Corp trades at $28.72 (market cap $15.12B). The key difference: DexCom, Inc. is far larger — about 2.1× Warner Music Group Corp's market cap, and Warner Music Group Corp pays a 2.77% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Warner Music Group Corp for 96 Days on average.
| DXCM | WMG | |
|---|---|---|
Market Cap | $31.86B | $15.12B |
Volume | 3,607,070 | 2,966,414 |
Sector | Health | Media |
52-Week High | $92.34 | $34.72 |
52-Week Low | $54.84 | $23.65 |
Typical Hold Time | 62 Days | 96 Days |
Enterprise Value | $31.32B | $19.42B |
Dividend Yield | — | 2.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Warner Music Group (WMG) trades at $28.91, up 2.66% on the day, with a bullish technical outlook and strong analyst support. Recent earnings have beaten expectations, with Q2 2026 EPS of $0.38 exceeding the $0.3435 forecast. The company's revenue growth is solid, projected to reach $7.3B in 2026, and it maintains a high return on equity of 92.72%. Positive news includes strategic AI partnerships and a renewed licensing deal with NetEase Cloud Music.
The stock presents a compelling opportunity with a consensus price target of $39.50, implying significant upside. However, risks include recent net cash outflows, a high P/E ratio of 23.12, and competitive pressures in the evolving music industry. Investor sentiment is buoyed by institutional buying and AI-driven growth prospects, but execution on cost management and streaming market share remains critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
